Document is current

Article History

Accepted: 16 July 2024

First Online: 31 July 2024

Declarations

:

: No external funding was used in the preparation of this manuscript.

: <b>Financial interests:</b> Dr. R. ter Heine receives research funding from AMGEN. All payments are outside of the submitted work. Dr. A. J. van der Wekken reports research grants from Astra-Zeneca, Boehringer-Ingelheim, Roche, Pifeze, and Takeda; consulting fees from Amgen, Astra-Zeneca, Boehringer-Ingelheidm, Janssen, Lilly, Merck, Novartis, Roche, Pfizer, and Takeda; and honoraria for lectures from Astra-Zeneca and Roche. All payments are outside of the submitted work. <b>Nonfinancial interests:</b> Dr. A.J. van der Wekken is a member of Leadership in FMS and NVALT ‘dure geneesmiddelen’, NFU quickscan group, Guideline committee member NSCLC and CUP, KNT committee and ROS1ders advisory board. All intuitions are outside of the submitted work. Authors MSc. M.P. Kicken, Dr. M.J. Deenen, Dr. D.J.A.R. Moes, Dr. J.J.M.A. Hendrikx, Dr. B.E.E.M. van den Borne, Dr. D.W. Dumoulin, and Dr. M. M. van den Heuvel declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

: Not applicable.

: Not applicable.

: Not applicable.

: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. The model code used for simulation of different dose regimens is found in the Supplementary Material.

: We used simulated data as mentioned in the methods. We provided references and settings/distribution of our simulated population in the methods section using PopGen [].